Page last updated: 2024-12-08

sulindac

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1548887
CHEMBL ID15770
CHEBI ID9352
CHEBI ID93811
SCHEMBL ID4203
SCHEMBL ID4202
MeSH IDM0020810
PubMed CID1548885
CHEMBL ID1376
SCHEMBL ID755984
MeSH IDM0020810

Synonyms (233)

Synonym
LS-14757
2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
HY-B0008
AB00052105-07
BRD-A13946108-001-04-9
cis-5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1h-indene-3-acetic acid
cis-5-fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid
sulindacum
sulindaco
{(1z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid
clinoril
CHEBI:9352 ,
(z)-5-fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1h-indene-3-acetic acid
sulindacum [inn-latin]
brn 2951842
einecs 253-819-2
ccris 3305
sulindaco [inn-spanish]
1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (z)-
mobilin
arthrocine
EU-0101070
sulindac (jp17/usp/inn)
D00120
clinoril (tn)
NCGC00025268-01
NCGC00015970-01
NCGC00015970-02
lopac-s-8139
cas-38194-50-2
tocris-1707
LOPAC0_001070
BSPBIO_002890
BPBIO1_000315
PRESTWICK3_000073
SPECTRUM5_001024
AB00513800
C01531
sulindac
sulindac, meets usp testing specifications
DB00605
NCGC00025268-03
smr000326718
NCGC00025268-02
MLS001056554
SPECTRUM1500556
CMAP_000021
IDI1_000601
BSPBIO_000285
NCGC00094349-02
NCGC00094349-01
sulindac, >=98.0%
NCGC00015970-03
S 8139 ,
(z)-5-fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1h-indene-3-acetic acid
HMS2092K15
NCGC00015970-08
aflodac
artribid
nsc-757344
CHEMBL15770 ,
HMS501O03
HMS1921C11
bdbm50012899
HMS2095O07
HMS3259K06
HMS3263E22
5-fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1h-indene-3-acetic acid
einecs 250-893-8
NCGC00255143-01
dtxcid703624
tox21_301418
dtxsid4023624 ,
1h-indene-3-aceticacid, 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-, (1z)-
pharmakon1600-01500556
nsc757344
tox21_110270
(z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1h-inden-3-yl)acetic acid
HMS2231N24
CCG-39264
NCGC00015970-05
NCGC00015970-04
NCGC00015970-06
NCGC00015970-07
1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-, (1z)-
2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylene]inden-1-yl]acetic acid
moblilin
sulindac [usan:usp:inn:ban:jan]
cis-sulindac
184sns8vuh ,
citireuma
cis-5-fluoro-2-methyl-1-((p-methylsulfinyl)benzylidenyl)indene-3-acetic acid
imbaral
einecs 256-402-3
nsc 757344
sulreuma
algocetil
clisundac
reumofil
(z)-(1)-5-fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1h-indene-3-acetic acid
sudac
sulinol
unii-184sns8vuh
LP01070
CS-0569
S2007
AKOS015895412
2-[(1z)-5-fluoro-1-[(4-methanesulfinylphenyl)methylidene]-2-methyl-1h-inden-3-yl]acetic acid
gtpl5425
BP-30208
sulindac [inci]
sulindac [mi]
sulindac [jan]
sulindac [who-dd]
1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (1z)-
sulindac [inn]
sulindac [usan]
sulindac [orange book]
sulindac [ep monograph]
sulindac [mart.]
sulindac [usp monograph]
sulindac [usp-rs]
sulindac [vandf]
NC00540
SCHEMBL4203
SCHEMBL4202
NCGC00015970-11
tox21_110270_1
KS-5153
tox21_501070
NCGC00261755-01
MLKXDPUZXIRXEP-MFOYZWKCSA-N
(z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)-phenyl]methylene]-1h-indene-3-acetic acid
sulindac|(1z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1h-indene-3-acetic acid
HMS3649P19
AB00052105_08
AB00052105_09
SR-01000075237-2
sr-01000075237
CHEBI:93811
sulindac, united states pharmacopeia (usp) reference standard
{(1z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-indene-3-yl}acetic acid
bdbm50103504
sulindac, european pharmacopoeia (ep) reference standard
J-008554
J-012337
SR-01000075237-3
SR-01000075237-5
SR-01000075237-7
SBI-0051040.P004
HMS3712O07
SW219748-1
HMS3678N09
(z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)-benzylidene)-1h-inden-3-yl)acetic acid
SR-01000075237-13
U0099
(z)-5-fluoro-2-methyl-1-[(p-methylsulfinyl)benzylidene]-1h-indene-3-acetic acid
(z)-2-[5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl]acetic acid
HMS3414N11
Q963093
BRD-A13946108-001-08-0
SDCCGSBI-0051040.P005
NCGC00381714-10
HMS3884K18
(s,z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1h-inden-3-yl)acetic acid
sulindac 100 microg/ml in acetonitrile
BS166205
EN300-7363233
(z)-5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1h-indene-3-acetic acid
sulindac (usan:usp:inn:ban:jan)
sulindac (ep monograph)
sulindac (usp monograph)
((1z)-5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1h-inden-3-yl)acetic acid
m01ab02
sulindac (usp-rs)
sulindacum (inn-latin)
(1z)-(5-fluoro-2-methyl-1-(4-((rs)-methylsulfinyl)benzylidene)-lh-inden-3-yl)acetic acid
sulindaco (inn-spanish)
cis-5-fluoro-2-methyl-1-(p-(methylsulfinyl)benzylidene)indene-3-acetic acid
sulindac (mart.)
MLS002207124
AC-4550
2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
BRD-A03427350-001-01-3
PRESTWICK2_000073
[(1e)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1h-inden-3-yl]acetic acid
mk-231
mk 231
sulindac sulfoxide
PRESTWICK_456
38194-50-2
smr000043852
MLS001304027
HMS2089J04
UNM-0000306136 ,
CHEMBL1376
r-sulindac sulfoxide
HMS1568O07
STK802068
{(1e)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid
AKOS004119989
NCGC00188951-01
BBL010958
HMS2233D04
trans-sulindac
1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (e)-
5nvo8803f9 ,
53933-60-1
unii-5nvo8803f9
einecs 258-873-0
sulindac, trans-
(e)-(1)-5-fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1h-indene-3-acetic acid
sulindac impurity a [ep impurity]
(e)-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1h-inden-3-yl)acetic acid
sulindac, trans-(+/-)-
1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (1e)-
SCHEMBL755984
((1z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl)acetic acid
MLKXDPUZXIRXEP-RQZCQDPDSA-N
reumyl
2-[(3e)-6-fluoro-2-methyl-3-(4-methylsulfinylbenzylidene)inden-1-yl]acetic acid
2-[(3e)-6-fluoranyl-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]ethanoic acid
2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]-1-indenyl]acetic acid
bdbm54707
cid_1548885
mfcd00599589
(e)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1h-inden-3-yl)acetic acid
(1z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1h-indene-3-acetic acid
49627-22-7
sulindac (clinoril)
Q27262612
DTXSID90860554
sulindac related compound a (20 mg) (trans-sulindac)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In the pirazolac group 15% of the patients and in the sulindac group 11% dropped out from the study due to adverse clinical experience."( Multicentre double-blind study of the efficacy, safety and tolerance of pirazolac compared with sulindac in patients with rheumatoid arthritis.
Numo, R, 1990
)
0.28
"Retrospective analysis of adverse event databases."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
"Reports of adverse events submitted to the FDAs Spontaneous Reporting System and the Adverse Event Reporting System from January 1969-December 2000 for these drugs were analyzed according to the number of adverse events reported for each drug per year from the time the drug was approved until December 2000."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
" Various other factors affected spontaneous reporting of adverse events, as peaks in the number of reports were seen numerous times for each drug after the initial 5-year marketing period."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" However, this group of drugs is associated with serious adverse drug reactions."( Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs.
Unlü, B; van Leeuwen, JS; Vermeulen, NP; Vos, JC, 2012
)
0.38
"Topical application of PSH is efficacious and safe in the treatment of Freund's adjuvant-induced arthritis; has a favorable pharmacokinetic profile; and likely acts by suppressing key pro-inflammatory signaling pathways."( Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.
Cheng, KW; Huang, L; Mackenzie, GG; Mattheolabakis, G; Ouyang, N; Rigas, B, 2013
)
0.39
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Pharmacokinetics

Sulindac sulfone half-life was highly variable and longer in the patient group. A dose of 150 mg gave significantly smaller values than the higher doses. There was no significant difference between 175 mg and 200 mg in sulindAC sulfide and sulfone concentrations.

ExcerptReferenceRelevance
" This was accomplished by generating parent drug and metabolite plasma level profiles assuming formation and excretion rate-limited pharmacokinetic models with absorption rate constants obtained from bivariate normal distributions and designated random errors."( The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.
Chen, ML; Jackson, AJ, 1991
)
0.28
" A pharmacokinetic model for reversible metabolism was used to characterize the kinetic parameters for sulindac----sulfide interconversion system."( Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
Duggan, DE; Lin, JH; Yeh, KC,
)
0.13
"The reciprocal effects on pharmacokinetic parameters after a single oral dose of the nonsteroidal antiinflammatory drugs (NSAIDs) indomethacin and sulindac and repeated oral doses of the H2-receptor antagonists cimetidine and ranitidine were determined in two groups of nine healthy subjects each (indomethacin and sulindac groups)."( Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers.
Abel, L; Carbon, C; Delhotal-Landes, B; Flouvat, B; Liote, F; Meyer, P; Vinceneux, P, 1988
)
0.27
" In addition, ibuprofen can be combined with acetaminophen without altering the pharmacokinetic profile."( Pharmacokinetics of ibuprofen.
Albert, KS; Gernaat, CM, 1984
)
0.27
" As judged from several pharmacokinetic parameters, a dose of 150 mg gave significantly smaller values than the higher doses but there was no significant difference between 175 mg and 200 mg in sulindac sulfide and sulfone concentrations."( Pharmacokinetics of graded oral doses of sulindac in man.
Lamminsivu, U; Männistö, P; Mäntylä, R; Mattila, J; Vuorela, A, 1984
)
0.27
" The administration of I or S with M significantly blunted sodium excretion on a purely pharmacodynamic basis while the decline in urinary potassium excretion upon addition of I to M related probably to an attenuation of braking phenomenon induced kaliuresis."( The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.
Gehr, TW; Kish, C; Ripley, EB; Sica, DA; Wade, J; Wallace, H, 1994
)
0.29
" Sulindac sulfone half-life was highly variable and longer in the patient group."( Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
Campagna, KD; Clark, CR; Diskin, CJ; McMillian, CL; Ravis, WR, 1993
)
0.29
" Pharmacokinetic analysis did not demonstrate a clear effect of exisulind on docetaxel pharmacokinetics and vice versa."( A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Baron, A; Basche, M; Bunn, PA; Chan, DC; Eckhardt, SG; Gibbs, A; Gustafson, DL; Holden, SN; Kelly, K; Long, ME; Menter, A; O'Bryant, CL; Pallansch, P; Persky, M; Pierson, AS; Witta, SE; Zeng, C, 2004
)
0.32
" Correspondence in pharmacokinetic and pharmacodynamic profiles between the two dosing approaches cannot be assumed a priori."( Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.
Kapetanovic, IM; Krishnaraj, R; Lyubimov, A; Martin-Jimenez, T; van Breemen, RB; Yuan, L, 2006
)
0.33
" Pharmacokinetic studies were performed to characterize the plasma disposition of OSI-461 and the effect of food intake on OSI-461 absorption."( A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
Basche, M; Boinpally, R; Chow, L; Diab, S; Eckhardt, SG; Gibbs, A; Gore, L; Hariharan, S; Leonardi, K; Leong, S; Lieu, CH; O'Bryant, CL; Schultz, MK, 2009
)
0.35
" Pharmacokinetic studies of OSI-461 revealed approximately a twofold increase in AUC(0-24) when OSI-461 was administered with food."( A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
Basche, M; Boinpally, R; Chow, L; Diab, S; Eckhardt, SG; Gibbs, A; Gore, L; Hariharan, S; Leonardi, K; Leong, S; Lieu, CH; O'Bryant, CL; Schultz, MK, 2009
)
0.35
"Toxicity and pharmacodynamic data show that the recommended oral dose of OSI-461 is 800 mg twice daily administered with food."( A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
Basche, M; Boinpally, R; Chow, L; Diab, S; Eckhardt, SG; Gibbs, A; Gore, L; Hariharan, S; Leonardi, K; Leong, S; Lieu, CH; O'Bryant, CL; Schultz, MK, 2009
)
0.35
"CYPs and FMOs play an important role in the metabolism of phospho-NSAIDs, resulting in differential pharmacokinetic profiles between phospho-NSAIDs and NSAIDs in vivo."( Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.
Cheng, KW; Constantinides, PP; Huang, L; Rigas, B; Wong, CC; Xie, G, 2012
)
0.38
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38
" To further current understanding of sulindac bioavailability, metabolism, and disposition, we developed a population pharmacokinetic model for the parent compound and its active metabolites, sulindac sulfide, and exisulind."( Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.
Ames, MM; Berg, AK; Boring, D; Carlson, EC; Limburg, PJ; Mandrekar, SJ; Reid, JM; Szabo, E; Ziegler, KL, 2013
)
0.39
" Both formulations of curcumin significantly improved the pharmacokinetic profiles of PS, with the 10% Tween-80 suspension being much more effective than the nanoparticle formation."( Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.
Cheng, KW; Huang, L; Mattheolabakis, G; Rigas, B; Wong, CC; Xie, G, 2013
)
0.39
" In the population pharmacokinetic analysis, one depot compartment model of sulindac with absorption lag time best described the data."( Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.
Chung, JE; Gwak, HS; Kim, YJ; Lee, KE; Park, S; Song, B; Sung, JW; Yee, J; Yun, HY, 2020
)
0.56
"The purpose of this study is to determine whether the occurrence of herb-drug interaction (HDI) caused by PM is associated with cytochrome P450 (CYP450) based on pharmacokinetic studies and in vitro inhibition assays."( Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays.
Bi, Y; Cai, W; Fu, Z; Han, L; Xing, Y; Yu, Q; Zhang, Y; Zhou, L, 2023
)
0.91

Compound-Compound Interactions

P-S/DFMO is an efficacious drug combination for colon cancer prevention and also show the safety of P-S, which may overcome the limiting side effects of conventional sulindac.

ExcerptReferenceRelevance
" These findings suggest that SAMC may be useful in colon cancer prevention when used alone or in combination with SS or other chemopreventive agents."( Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide.
Delohery, T; Holt, PR; Kawabata, Y; Moss, SF; Murty, V; Pinto, JT; Rivlin, RS; Shirin, H; Soh, JW; Weinstein, IB, 2001
)
0.31
" To design successful therapeutic strategies involving compounds either alone or in combination with others, it is necessary to understand their mechanism of action."( Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
Crowell, PL; Jung, SH; Marshall, MS; Sweeney, CJ; Yip-Schneider, MT, 2001
)
0.31
" In this report, we evaluated the effects of exisulind, a novel proapoptotic agent that is a sulfone metabolite of sulindac, in combination with docetaxel on the growth of the human non-small cell lung cancer cell line A549 in vitro and in vivo."( Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Alila, H; Baron, A; Bunn, PA; Chan, DC; Earle, KA; Helfrich, B; Nelson, P; Pamukcu, R; Piazza, G; Thompson, WJ; Whitehead, CM; Zeng, C; Zhao, TL, 2002
)
0.31
"We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)."( Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH, 2003
)
0.32
"Exisulind (125 mg orally bid) in combination with capecitabine is well tolerated and the combination has anticancer activity similar to that of capecitabine alone in heavily pretreated patients with MBC."( Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH, 2003
)
0.32
"To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells."( Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
Ma, L; Xie, YL; Yu, Y; Zhang, QN, 2005
)
0.33
" MMC combined with sulindac can suppress the growth of gastric cancer cells through induction of apoptosis mediated by down-regulation of apoptosis-related Bcl-2 and COX-2 gene."( Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
Ma, L; Xie, YL; Yu, Y; Zhang, QN, 2005
)
0.33
"0) in combination with exisulind (125-250 mg orally twice daily)."( A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Kuhn, JG; Raefsky, EL; Thompson, DS; White, MB; Willcutt, NT, 2005
)
0.33
"We conducted a dose-escalating, single arm, prospective, open label, non-randomised phase I trial of epirubicin (75 mg/m(2)) in combination with escalating oral doses of sulindac (0-800 mg) in patients with advanced cancer to identify an appropriate dose of sulindac to use in future resistance studies."( A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
Arnold, RD; Ballot, J; Clynes, M; Collins, CD; Crown, J; Fennelly, D; Kennedy, S; Kinsella, P; Larkin, A; Mager, DE; O'Connor, R; O'Driscoll, L; O'Leary, M, 2007
)
0.34
"The rats that received celecoxib in combination with exisulind at low doses showed a significant decrease in prostatic intraepithelial neoplasia and adenocarcinomas as well as an enhanced rate of apoptosis."( Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Bosland, MC; Horton, L; Narayanan, BA; Narayanan, NK; Nargi, D; Randolph, C; Reddy, BS, 2007
)
0.34
"To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors."( A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011
)
0.37
"This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m(2) given on Day 1 of each 21-day cycle."( A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011
)
0.37
" Study results show that P-S/DFMO is an efficacious drug combination for colon cancer prevention and also show the safety of P-S, which may overcome the limiting side effects of conventional sulindac."( Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Huang, L; Komninou, D; Kopelovich, L; Mackenzie, GG; Ouyang, N; Rigas, B; Sun, Y; Vrankova, K; Xie, G, 2011
)
0.37
"The purpose of the study was to characterize the involvement of reactive oxygen species (ROS) in mediating the cytotoxic effects of arsenic trioxide (ATO) in combination with sulindac or its metabolites: sulfide (SS) and sulfone (SF) on human leukemic cell lines."( Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leu
Arkusz, J; Ferlińska, M; Gradecka-Meesters, D; Smok-Pieniążek, A; Stańczyk, M; Stępnik, M, 2012
)
0.38
"Intervention with DMAPT and sulindac in combination with gemcitabine may delay or prevent progression of premalignant pancreatic lesions in the LSL-Kras(G12D);Pdx-1-Cre mouse model of pancreatic cancer."( Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Crooks, PA; Hruban, RH; Lowy, AM; Schmidt, CM; Wu, H; Yip-Schneider, MT, 2013
)
0.39
"A systematic investigation of the chemopreventive effect of sulindac (SL) in combination with either epigallocatechin gallate (EGCG) or kaempferol similar (KMP) has been carried out 1,2-dimethyl hydrazine-treated rats (DMH)."( Chemopreventive effect of sulindac in combination with epigallocatechin gallate or kaempferol against 1,2-dimethyl hydrazine-induced preneoplastic lesions in rats: A Comparative Study.
Elahl, HMS; Hassan, ESG; Hassanein, NMA; Hegab, AM, 2018
)
0.48
" The pharmacokinetics of sulindac (a representative of commonly used nonsteroidal anti-inflammatory drugs) and psoralen (a major compound of Psoralea in combination with PM) in rat plasma were studied when combined with raw and different processed products of PM."( Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays.
Bi, Y; Cai, W; Fu, Z; Han, L; Xing, Y; Yu, Q; Zhang, Y; Zhou, L, 2023
)
0.91

Bioavailability

The bioavailability of sulindac (SDC), a nonsteroidal anti-inflammatory drug, is low due to poor aqueous solubility and poor dissolution rate. This randomized, double-blind, placebo-controlled trial was conducted in individuals with atypical nevi.

ExcerptReferenceRelevance
" This was accomplished by generating parent drug and metabolite plasma level profiles assuming formation and excretion rate-limited pharmacokinetic models with absorption rate constants obtained from bivariate normal distributions and designated random errors."( The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.
Chen, ML; Jackson, AJ, 1991
)
0.28
" The estimated potency of aldose reductase inhibition for each of the three drugs in this study was significantly discrepant from the in vitro studies indicating the complicated nature of the bioavailability of a pharmaceutical agent in vivo, especially where pharmacologically active metabolites of a given drug are involved."( In vivo pharmacokinetics of aldose reductase inhibitors: 3-fluoro-3-deoxy-D-glucose NMR studies in rat brains.
Kwee, IL; Nakada, T, 1989
)
0.28
" Azapropazone has been found to be well absorbed, and benoxaprofen and fenclofenac somewhat more slowly, so for the latter two drugs their low rate of absorption might also be a factor in their reduced ulcerogenicity."( Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs of varying ulcerogenicity.
Rainsford, KD, 1986
)
0.27
" The study on bioavailability of 3H-EGCG in mice revealed the wide distribution of radioactivity in multiple organs."( Green tea and cancer chemoprevention.
Fujiki, H; Imai, K; Matsuyama, S; Nakachi, K; Okabe, S; Sueoka, E; Sueoka, N; Suganuma, M, 1999
)
0.3
" Preclinical studies revealed good oral bioavailability and no toxicity in dogs and rats at single doses up to 500 mg/kg."( Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.
Algazy, K; Alila, H; Gallo, JM; Giantonio, B; Haller, D; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W, 2002
)
0.31
" Encapsulation of the parent compound (sulindac sulfoxide) can be readily accomplished, but the effects of alternate formulations on bioavailability have not been rigorously examined."( Comparative bioavailability of sulindac in capsule and tablet formulations.
Ames, MM; Boring, D; Carlson, EC; Green, EM; Harmsen, WS; Limburg, PJ; Mandrekar, SJ; McGovern, RM; Reid, JM; Szabo, E, 2008
)
0.35
" The drug appears to be well-tolerated, and overall bioavailability appears to be markedly increased when the drug is administered with food."( A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
Basche, M; Boinpally, R; Chow, L; Diab, S; Eckhardt, SG; Gibbs, A; Gore, L; Hariharan, S; Leonardi, K; Leong, S; Lieu, CH; O'Bryant, CL; Schultz, MK, 2009
)
0.35
"This randomized, double-blind, placebo-controlled trial of sulindac was conducted in individuals with atypical nevi (AN) to determine bioavailability of sulindac and metabolites in nevi and effect on apoptosis and vascular endothelial growth factor A (VEGFA) expression in AN."( Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.
Alberts, DS; Chow, HH; Curiel-Lewandrowski, C; Einspahr, JG; Hsu, CH; Nagle, R; Parnes, H; Sagerman, P; Swetter, SM; Tangrea, J, 2012
)
0.38
" Moreover, the model quantifies the relative bioavailability of the sulindac formulations and illustrates the utility of population pharmacokinetics in bioequivalence assessment."( Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.
Ames, MM; Berg, AK; Boring, D; Carlson, EC; Limburg, PJ; Mandrekar, SJ; Reid, JM; Szabo, E; Ziegler, KL, 2013
)
0.39
"The bioavailability of sulindac (SDC), a nonsteroidal anti-inflammatory drug, is low due to poor aqueous solubility and poor dissolution rate."( Effect of Sulindac Binary System on In Vitro and In Vivo Release Profiles: An Assessment of Polymer Type and Its Ratio.
Shazly, GA, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56

Dosage Studied

Sulindac dosing resulted in accumulation of the drug and its sulfone and sulfide metabolites in plasma to a greater extent than previously reported for young subjects. Alternative dosing regimens of sulindac were evaluated for their chemoprevention effectiveness in the azoxymethane-treated A/J mouse model of colorectal cancer.

ExcerptRelevanceReference
" Data were compared to those obtained previously in ten healthy volunteers who received the same dosage regimen."( [Pharmacokinetics of sulindac in aged patients presenting with inflammatory joint disease].
Couet, W; Dourthe, C; Fourtillan, JB; Lefebvre, MA; Marechaud, R; Mignot, A,
)
0.13
" However, the baseline control collections after chronic dosing did not differ from the no-drug control periods."( Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics.
Anderson, SA; Brater, DC; Brown-Cartwright, D; Toto, RD, 1986
)
0.27
" Aspirin, at a dosage that almost completely inhibits both circulating cell and renal arachidonate metabolites, worsens the morphologic expression of rabbit nephrotoxic nephritis and negatively influences the clinical course of the disease."( Effect of aspirin and sulindac in rabbit nephrotoxic nephritis.
Benigni, A; Bertani, T; Carminati, C; Cutillo, F; Morelli, C; Remuzzi, G; Rocchi, G; Verroust, P, 1986
)
0.27
" By the fifth hospital day the patient's skin lesions and conjunctivitis had improved to the point that the prednisone dosage was tapered to 120 mg, then to 80 mg, and then to nothing over the following three days."( Sulindac-induced toxic epidermal necrolysis.
Garnett, WR; Small, RE, 1988
)
0.27
" In this patient, dosing with ibuprofen caused pronounced declines in all urinary prostanoids and a decrease in creatinine clearance."( Reversible acute decrease in renal function by NSAIDs in cirrhosis.
Anderson, SA; Brater, DC; Brown-Cartwright, D, 1987
)
0.27
" Patients undergoing lithium therapy might need a reduction of their lithium dosage following naproxen administration."( Lithium interaction with sulindac and naproxen.
Powell, AL; Ragheb, M, 1986
)
0.27
"The effects of 2 days of oral dosing with sulindac (200 mg twice a day) or indomethacin (75 mg twice a day) on glomerular filtration rate, urinary excretion of prostaglandin E2, sodium homeostasis, and other renal function parameters were investigated in eight patients with chronic stable impaired renal function."( Acute renal effects of sulindac and indomethacin in chronic renal failure.
Berg, KJ; Talseth, T, 1985
)
0.27
" Renal function was measured before dosing and 24 hours and 28 days after oral sulindac."( Acute and chronic effects of sulindac on renal function in chronic renal disease.
Griffiths, P; Swainson, CP, 1985
)
0.27
" However, no change should be made to lithium dosage during the drop phase, to avoid marked fluctuations in serum lithium levels."( The effect of sulindac on lithium therapy.
Davies, J; Furnell, MM, 1985
)
0.27
" Chronic sulindac dosing resulted in accumulation of the drug and its sulfone and sulfide metabolites in plasma to a greater extent than previously reported for young subjects."( Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.
Hunter, T; MacDougall, B; Mitenko, PA; Owen, JA; Sitar, DS, 1985
)
0.27
" At steady state the area under the plasma concentration-time curve (AUC) over 24 hr for sulfide metabolite was greater after once-daily dosing (112 and 84 micrograms ."( Sulindac disposition when given once and twice daily.
Boppana, VK; Ferguson, RK; Holmes, GI; Monsell, K; Swanson, BN; Vlasses, PH, 1982
)
0.26
" In therapeutic dosage it will adequately control joint symptoms in the majority of patients."( Pharmacotherapy of juvenile rheumatoid arthritis.
Lindsley, CB, 1981
)
0.26
" beginning 2 weeks prior to NMBA treatment) or following completion of NMBA dosing only."( Effects of dietary phenethyl isothiocyanate, ellagic acid, sulindac and calcium on the induction and progression of N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats.
Barch, DH; Siglin, JC; Stoner, GD, 1995
)
0.29
" Urine samples were obtained over 36 hours post-metolazone dosing for the determination of sodium, potassium and metolazone concentration."( The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.
Gehr, TW; Kish, C; Ripley, EB; Sica, DA; Wade, J; Wallace, H, 1994
)
0.29
" Based on the decreased plasma concentration of the active sulindac sulfide metabolite in the patient group, dosage adjustments may be required in patients with end-stage renal failure."( Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
Campagna, KD; Clark, CR; Diskin, CJ; McMillian, CL; Ravis, WR, 1993
)
0.29
"The absorption of sulindac from two different 200 mg oral dosage forms, Pro-SorbTM liquid and Clinoril tablets, was compared following administration to eight healthy human volunteers."( Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation.
Brown, C; Kanfer, I; Konings, M; Swarbrick, J, 1996
)
0.29
" Time course and dose-response experiments demonstrated that increased apoptosis paralleled the growth-inhibitory effects of the sulfide and sulfone."( Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Ahnen, DJ; Finn, TS; Fryer, BH; Li, H; Pamukcu, R; Piazza, GA; Rahm, AK; Stoumen, AL, 1997
)
0.3
" Sulfone-treated rats also showed a dose-response relationship for inhibiting all tumor parameters."( Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
Ahnen, DJ; Alberts, DS; Bogert, C; Brendel, K; Burt, RW; Ellsworth, L; Finn, T; Gross, PH; Guillen, JM; Hixson, LJ; Li, H; Pamukcu, R; Paranka, NS; Piazza, GA; Ritchie, J; Sperl, G, 1997
)
0.3
"We have determined the dose-response relationship between sulindac administration and inhibition of tumour growth in the rat."( Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat.
Charalambous, D; O'Brien, PE; Skinner, SA, 1998
)
0.3
" Opaque glucose base tablets were given at 4-hour intervals in the sulindac treatment arm to mimic the dosing interval in the terbutaline arm of the study."( A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor.
Belfort, M; Dorman, K; Kramer, WB; Mayes, M; Moise, KJ; Saade, GR, 1999
)
0.3
" To directly evaluate the ability of 5-ASA to suppress intestinal tumors, we studied several formulations of 5-ASA (free acid, sulfasalazine, and Pentasa) at multiple oral dosage levels [500, 2400, 4800, and 9600 parts/million (ppm)] in the adenomatous polyposis coli (Apc) mouse model of multiple intestinal neoplasia (Min)."( Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Gendler, SJ; Hirsch, RE; Leighton, JA; Morrow, JD; Ritland, SR; Weaver, AL, 1999
)
0.3
" Blood samples were taken before and up to 6 h after dosing and the plasma obtained from it was tested for its ability to inhibit prostanoid formation in IL-1beta-treated A549 cells (COX-2 system) and human washed platelets (COX-1 system)."( Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
Giuliano, F; Warner, TD, 1999
)
0.3
"Colorectal mucosal prostaglandin levels, but not ornithine decarboxylase or polyamines, may be valuable biomarkers to assess appropriate drug dosage and medication compliance in patients undergoing primary chemoprevention therapy with sulindac."( Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
Casero, RA; Geiman, DE; Giardiello, FM; Hamilton, SR; Hubbard, W; Hylind, LM; Judge, KR; Offerhaus, GJ; Trimbath, JD; Yang, VW, 2004
)
0.32
"A 12 month, multicentre, randomised, double blind, placebo controlled, phase 3, dose-response study was carried out."( Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study.
Arber, N; Hultcrantz, R; Kuwada, S; Leshno, M; Rex, D; Sjodahl, R, 2006
)
0.33
" Correspondence in pharmacokinetic and pharmacodynamic profiles between the two dosing approaches cannot be assumed a priori."( Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.
Kapetanovic, IM; Krishnaraj, R; Lyubimov, A; Martin-Jimenez, T; van Breemen, RB; Yuan, L, 2006
)
0.33
"A promising approach for cancer chemoprevention might be a combination therapy utilizing dietary phytochemicals and anticarcinogenic pharmaceuticals at a suboptimal dosage to minimize any potential adverse side effects."( Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC(Min) mice fed suboptimal levels of sulindac.
Bobe, G; Bourquin, LD; Nair, MG; Seeram, NP; Wang, B, 2006
)
0.33
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" Dosing studies with three known inhibitors of Abeta production, sulindac sulfide (SSide), BMS-299897 ('897) and compound W (CW) are reported to demonstrate the utility and analytical characteristics of the assay."( Qualitative and quantitative characterization of the amyloid beta peptide (Abeta) population in biological matrices using an immunoprecipitation-LC/MS assay.
Cantone, JL; Drexler, DM; Ford, MJ; Meredith, JE; Polson, C; Toyn, JH, 2008
)
0.35
" In the human HT-29 colon tumor xenograft mouse model, SSA significantly inhibited tumor growth at a dosage of 250 mg/kg."( A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.
Coward, L; Gary, BD; Gorman, G; Hobrath, JV; Keeton, AB; Li, Y; Mathew, B; Maxuitenko, YY; Piazza, GA; Reynolds, RC; Sani, B; Thaiparambil, J; Tinsley, HN; Whitt, JD, 2009
)
0.35
"This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m(2) given on Day 1 of each 21-day cycle."( A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Facilitation of osteoblast apoptosis occurred regardless of IND dosage under hypoxic conditions."( Facilitation of human osteoblast apoptosis by sulindac and indomethacin under hypoxic injury.
Chang, CH; Chen, YC; Fan, SC; Huang, CH; Liu, C; Tsai, AL; Wu, CC, 2012
)
0.38
" This raises the question of whether intermittent dosing schedules might reduce toxicity while retaining benefit, a concept that we call short-term intermittent therapy to eliminate premalignancy (SITEP)."( An intermittent approach for cancer chemoprevention.
Lippman, SM; Wu, X, 2011
)
0.37
" In this study, alternative dosing regimens of sulindac were evaluated for their chemoprevention effectiveness in the azoxymethane-treated A/J mouse model of colorectal cancer."( Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.
Barton, JK; Chandra, S; Gerner, EW; Nymeyer, AC; Rice, PF, 2017
)
0.46
"The mean maternal and gestational ages at the time of dosing were 32."( Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.
Chung, JE; Gwak, HS; Kim, YJ; Lee, KE; Park, S; Song, B; Sung, JW; Yee, J; Yun, HY, 2020
)
0.56
" Dosage and delivery pattern were essential for effectiveness."( Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study.
Haub, K; Holinski-Feder, E; Laner, A; Locher, M; Morak, M; Neuhann, TM; Steinke-Lange, V, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
tocolytic agentAny compound used to suppress premature labour and immature birth by suppressing uterine contractions.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
monocarboxylic acidAn oxoacid containing a single carboxy group.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Sulindac Action Pathway2967

Protein Targets (97)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency24.03530.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency26.67950.100020.879379.4328AID488773; AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency48.96623.189029.884159.4836AID1224846
SMAD family member 2Homo sapiens (human)Potency24.34560.173734.304761.8120AID1346859; AID1346924
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
SMAD family member 3Homo sapiens (human)Potency24.34560.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency26.29410.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency61.13060.000714.592883.7951AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency29.90330.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency35.89520.000221.22318,912.5098AID743036; AID743053
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.01630.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency49.12670.001022.650876.6163AID1224838; AID1224839; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency26.67950.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.34390.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.57120.001530.607315,848.9004AID1224841; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency21.68990.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.02830.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency25.57120.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency43.64120.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency30.89560.023723.228263.5986AID743222
arylsulfatase AHomo sapiens (human)Potency26.85451.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency27.73750.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency18.00750.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency61.13060.001628.015177.1139AID1224843
activating transcription factor 6Homo sapiens (human)Potency21.31380.143427.612159.8106AID1159516
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00000.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.39440.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency35.48130.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency35.48130.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.03980.039816.784239.8107AID995
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency31.93030.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency0.23110.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency8.23990.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency12.43120.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.00560.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency15.84890.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency27.54040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency8.23991.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.00540.060110.745337.9330AID485368
thioredoxin reductaseRattus norvegicus (Norway rat)Potency35.48130.100020.879379.4328AID588453
thioredoxin glutathione reductaseSchistosoma mansoniPotency19.95260.100022.9075100.0000AID485364
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency14.58100.004611.374133.4983AID624296
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency11.22020.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E synthaseHomo sapiens (human)IC50 (µMol)80.00000.00102.030810.0000AID620116
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Aldo-keto reductase family 1 member B10Homo sapiens (human)IC50 (µMol)2.69000.00101.94459.6000AID1802103
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)87.50000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)139.42250.11007.190310.0000AID1209455; AID1443980; AID1449628; AID1473738
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)10.00000.00000.536910.0000AID1264567
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)16.00000.00032.177410.0000AID1264568
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00462.018210.0000AID6860
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)2.69000.00101.191310.0000AID1802103
Aldo-keto reductase family 1 member B1Bos taurus (cattle)IC50 (µMol)0.29300.00702.589210.0000AID1801947
Retinoic acid receptor RXR-alphaHomo sapiens (human)IC50 (µMol)82.90000.00600.44502.4000AID734227
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)8.80000.00010.995010.0000AID1264569
Lactoylglutathione lyaseHomo sapiens (human)Ki108.45000.00122.59479.1400AID568008; AID568009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Complement C5Homo sapiens (human)Kd0.57000.57000.62500.7100AID1601161
Glycine receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)0.38000.32001.45774.2000AID1203550
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)22.65000.00000.992210.0000AID1767809
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Kd100.00000.00120.95314.9800AID1767811
GTP-binding protein (rab7)Canis lupus familiaris (dog)EC50 (µMol)30.00000.02201.21466.4190AID2036
ras protein, partialHomo sapiens (human)EC50 (µMol)30.00000.02000.22371.9660AID2038; AID2043
Rac1 proteinHomo sapiens (human)EC50 (µMol)38.33300.02025.986029.5100AID2039; AID2040
cell division cycle 42 (GTP binding protein, 25kDa), partialHomo sapiens (human)EC50 (µMol)30.00000.05633.055413.5100AID2021; AID2022
Ras-related protein Rab-2ACanis lupus familiaris (dog)EC50 (µMol)30.00000.15800.37770.7042AID2046
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)30.00000.10601.07651.7000AID2038; AID2043
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (357)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin E synthaseHomo sapiens (human)
prostaglandin metabolic processProstaglandin E synthaseHomo sapiens (human)
signal transductionProstaglandin E synthaseHomo sapiens (human)
cell population proliferationProstaglandin E synthaseHomo sapiens (human)
negative regulation of cell population proliferationProstaglandin E synthaseHomo sapiens (human)
sensory perception of painProstaglandin E synthaseHomo sapiens (human)
regulation of fever generationProstaglandin E synthaseHomo sapiens (human)
positive regulation of prostaglandin secretionProstaglandin E synthaseHomo sapiens (human)
regulation of inflammatory responseProstaglandin E synthaseHomo sapiens (human)
cellular oxidant detoxificationProstaglandin E synthaseHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member B10Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
chemotaxisComplement C5Homo sapiens (human)
inflammatory responseComplement C5Homo sapiens (human)
complement activation, alternative pathwayComplement C5Homo sapiens (human)
complement activation, classical pathwayComplement C5Homo sapiens (human)
cell surface receptor signaling pathwayComplement C5Homo sapiens (human)
G protein-coupled receptor signaling pathwayComplement C5Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionComplement C5Homo sapiens (human)
negative regulation of macrophage chemotaxisComplement C5Homo sapiens (human)
killing of cells of another organismComplement C5Homo sapiens (human)
positive regulation of chemokine productionComplement C5Homo sapiens (human)
cell chemotaxisComplement C5Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
retinol metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlycine receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transportGlycine receptor subunit alpha-1Homo sapiens (human)
muscle contractionGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-1Homo sapiens (human)
acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
visual perceptionGlycine receptor subunit alpha-1Homo sapiens (human)
adult walking behaviorGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal action potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuromuscular process controlling postureGlycine receptor subunit alpha-1Homo sapiens (human)
negative regulation of transmission of nerve impulseGlycine receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, glycinergicGlycine receptor subunit alpha-1Homo sapiens (human)
righting reflexGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-1Homo sapiens (human)
response to alcoholGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-1Homo sapiens (human)
positive regulation of acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
carbohydrate metabolic processLactoylglutathione lyaseHomo sapiens (human)
regulation of transcription by RNA polymerase IILactoylglutathione lyaseHomo sapiens (human)
glutathione metabolic processLactoylglutathione lyaseHomo sapiens (human)
methylglyoxal metabolic processLactoylglutathione lyaseHomo sapiens (human)
osteoclast differentiationLactoylglutathione lyaseHomo sapiens (human)
negative regulation of apoptotic processLactoylglutathione lyaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
Golgi organizationRas-related protein Rab-2ACanis lupus familiaris (dog)
protein transportRas-related protein Rab-2ACanis lupus familiaris (dog)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (137)

Processvia Protein(s)Taxonomy
glutathione transferase activityProstaglandin E synthaseHomo sapiens (human)
glutathione peroxidase activityProstaglandin E synthaseHomo sapiens (human)
prostaglandin-D synthase activityProstaglandin E synthaseHomo sapiens (human)
protein bindingProstaglandin E synthaseHomo sapiens (human)
glutathione bindingProstaglandin E synthaseHomo sapiens (human)
prostaglandin-E synthase activityProstaglandin E synthaseHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B10Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
endopeptidase inhibitor activityComplement C5Homo sapiens (human)
signaling receptor bindingComplement C5Homo sapiens (human)
protein bindingComplement C5Homo sapiens (human)
chemokine activityComplement C5Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transmembrane signaling receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingGlycine receptor subunit alpha-1Homo sapiens (human)
zinc ion bindingGlycine receptor subunit alpha-1Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
taurine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lactoylglutathione lyase activityLactoylglutathione lyaseHomo sapiens (human)
protein bindingLactoylglutathione lyaseHomo sapiens (human)
zinc ion bindingLactoylglutathione lyaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
GTPase activityRas-related protein Rab-2ACanis lupus familiaris (dog)
GTP bindingRas-related protein Rab-2ACanis lupus familiaris (dog)
GDP bindingRas-related protein Rab-2ACanis lupus familiaris (dog)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (81)

Processvia Protein(s)Taxonomy
nuclear envelope lumenProstaglandin E synthaseHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
perinuclear region of cytoplasmProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
extracellular regionAldo-keto reductase family 1 member B10Homo sapiens (human)
lysosomeAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
mitochondrionAldo-keto reductase family 1 member B10Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular regionComplement C5Homo sapiens (human)
extracellular spaceComplement C5Homo sapiens (human)
extracellular exosomeComplement C5Homo sapiens (human)
membrane attack complexComplement C5Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
external side of plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
membraneGlycine receptor subunit alpha-1Homo sapiens (human)
dendriteGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal cell bodyGlycine receptor subunit alpha-1Homo sapiens (human)
perikaryonGlycine receptor subunit alpha-1Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory synapseGlycine receptor subunit alpha-1Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleoplasmLactoylglutathione lyaseHomo sapiens (human)
cytoplasmLactoylglutathione lyaseHomo sapiens (human)
cytosolLactoylglutathione lyaseHomo sapiens (human)
plasma membraneLactoylglutathione lyaseHomo sapiens (human)
extracellular exosomeLactoylglutathione lyaseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
autophagosome membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
acrosomal vesicleRas-related protein Rab-2ACanis lupus familiaris (dog)
endoplasmic reticulum membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
endoplasmic reticulum-Golgi intermediate compartment membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
melanosomeRas-related protein Rab-2ACanis lupus familiaris (dog)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (308)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1636505Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 28.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID105980Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK-f3 (Madin-Darby canine kidney f3) cell line2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New indene-derivatives with anti-proliferative properties.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1601155Binding affinity to recombinant human C5a assessed as conformational change at 1 to 100 uM incubated for 1 hr at 4degC by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1601163Binding affinity to human C5a assessed as loss of secondary structure by measuring red shift in absorption maxima at 10 to 100 uM by fluorescence analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID568009Inhibition of glyoxalase 12011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID535979Induction of apoptosis in human COLO320 cells assessed as DNA internucleosomal fragmentation at 200 uM after 48 hrs relative to control2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1743655Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1203551Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1223486Intrinsic clearance in human hepatocytes from chimeric mouse with humanized liver assessed per 10'6 cells at 10 uM after 0.25 to 2 hrs by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1077804Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1064298Cytotoxicity against human PC3 cells assessed as cell viability at 50 uM after 48 hrs by crystal violet method (Rvb = 100.87 +/- 4.87%)2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID6860Inhibition of 5-lipoxygenase in intact RBL-1 cell line1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
AID1064292Induction of NO release in glutathione buffer assessed as nitrite level at 400 uM after 1 hr by Griess assay (Rvb = 3.3 +/- 1.2 uM)2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1898637Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as Gibbs free energy change for binary complex by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1743654Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID105636Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK cells2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New indene-derivatives with anti-proliferative properties.
AID1601168Binding affinity to human C5a assessed as induction of conformational change with no shift in absorption maxima at 1 uM by fluorescence analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID540235Phospholipidosis-negative literature compound
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1136207Inhibition of PG synthase (unknown origin)1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID734227Displacement of [3H]-9-cis-RA from RXRalpha (unknown origin) by liquid scintillation counting2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1221980Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1136206Analgesic activity in po dosed rat assessed as inhibition of adjuvant-induced arthritis pain1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID592846Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as increase of amyloid beta (1 to 38) level at 10 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1601167Induction of human recombinant C5a destabilization assessed as protein structure helicity up to 10 uM by circular dichroism analysis (Rvb = 71%)2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID223805Inhibition of p21ras protein and Raf kinase in vitro using recombinant proteins (inactive)2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New indene-derivatives with anti-proliferative properties.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1898639Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as change in entropy for binary complex by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1223478Total clearance in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1898638Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as change in enthalpy binary by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1898641Inhibition of amyloid beta (1 to 42) (unknown origin) self aggregation after 24 hrs by thioflavin-T fluorescence method2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1529183Protein binding in immobilized human serum albumin after 15 mins by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1601166Induction of human recombinant C5a unfolding by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID144345Anti-proliferative activity was evaluated by its ability to inhibit proliferation of murine NIH3T3 fibroblasts2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New indene-derivatives with anti-proliferative properties.
AID684833Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: synthesis, biological evaluation, and mechanism investigation.
AID734230Inhibition of RXRalpha in human HepG2 cells assessed as inhibition of TNFalpha-induced Akt phosphorylation2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation.
AID1767809Partial agonist activity at GAL4 DBD-fused PPARgamma LBD (unknown origin) expressed in pG5 luc and pBIND transfected HEK293T cells assessed as transcriptional activation incubated for 12 hrs by fluorescence based luciferase assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1601157Binding affinity to recombinant human C5a assessed as loss of super secondary structure at > 10 uM incubated for 1 hr at 4 degC by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1221971Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1743648Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID535976Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.
AID1223484Unbound fraction in po dosed human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1264567Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.
AID1601164Binding affinity to human C5a assessed as Potassium iodide-induced quenching by measuring Stern-Volmer quenching constant at 1 uM by fluorescence analysis (Rvb = 4.1/M)2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1898636Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as complex dissociation constant by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1264568Inhibition of Ovine COX-1 preincubated for 15 mins by fluorescence analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.
AID1064297Cytotoxicity against human PC3 cells assessed as cell viability at 50 uM after 72 hrs by crystal violet method (Rvb = 95.69 +/- 7.66%)2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1743653Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1077767Antiinflammatory activity in carrageenan-induced Wistar rat model assessed as inhibition of PGE2 level at 200 mg/kg through gavage administered 1 hr prior to carrageenan-challenge measured after 4 hrs (Rvb = 95 +/- 7 pg/mL)
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID166562Anti-proliferative activity was evaluated by its ability to inhibit proliferation of rat embryonic fibroblasts (REF)2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New indene-derivatives with anti-proliferative properties.
AID1223475Elimination half life in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID734233Induction of apoptosis in human ZR75-1 cells assessed as PARP cleavage at 30 uM after 6 hrs by Western blot analysis2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation.
AID1136211Toxicity in po dosed rat assessed as gastric hemorrhage1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1767810Partial agonist activity at GAL4 DBD-fused PPARgamma LBD (unknown origin) expressed in pG5 luc and pBIND transfected HEK293T cells assessed as maximum fold induction incubated for 12 hrs by fluorescence based luciferase assay relative to control2021European journal of medicinal chemistry, Oct-15, Volume: 222Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID592845Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as increase of amyloid beta (1 to 37) level at 10 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID734231Inhibition of RXRalpha in human HCT116 cells assessed as inhibition of TNFalpha-induced Akt phosphorylation2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation.
AID239780Percentage plasma protein binding towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID1908940Induction of autophagy in human MIA PaCa-2 cells assessed as accumulation of WIP11 marker gene expression at upto 600 uM incubated for 72 hrs by Western blot analysis2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.
AID1223485Ratio of drug level in blood to plasma in po dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID620116Inhibition of microsomal PGES2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Novel human mPGES-1 inhibitors identified through structure-based virtual screening.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1077805Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID722836Inhibition of calf ALR22013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
Dual action spirobicycloimidazolidine-2,4-diones: antidiabetic agents and inhibitors of aldose reductase-an enzyme involved in diabetic complications.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1221821Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID592741Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrate production at 10 uM treated 30 mins before LPS challenge measured after 24 hrs by Griess reagent method relative to control2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID420789Analgesic activity in Albino mouse assessed as inhibition of acetic acid-induced writhing at 300 umol/kg, po administered 1 hr before acetic acid challenge and measured 10 mins after acetic acid challenge2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1601161Binding affinity to human C5a assessed as dissociation constant after 1 hr by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID104153The compound was evaluated for percent incorporation in DOPC vesicles, when compound to lipid mol ratio is 21981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Membrane effects of antiinflammatory agents. 1. Interaction of sulindac and its metabolites with phospholipid membrane, a magnetic resonance study.
AID1198262Antiproliferative activity against human U373MG cells assessed reduction in cell number at 10 uM incubated for 6 days by trypan blue dye exclusion dye based inverted microscopy2015European journal of medicinal chemistry, Mar-26, Volume: 93Effect of new hybrids based on 5,16-pregnadiene scaffold linked to an anti-inflammatory drug on the growth of a human astrocytoma cell line (U373).
AID1529185Protein binding in human serum albumin after 4.5 hrs by LC-MS based rapid equilibrium dialysis method2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID535978Induction of apoptosis in human MIAPaCa2 cells assessed as DNA internucleosomal fragmentation at 200 uM after 48 hrs relative to control2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1908941Induction of autophagy in human MIA PaCa-2 cells assessed as accumulation of GABARAPL1 marker gene expression at upto 600 uM incubated for 72 hrs by Western blot analysis2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.
AID1743650Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1221979Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1077771Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw volume at 200 mg/kg through gavage administered 1 hr prior to carrageenan-challenge measured after 4 hrs (Rvb = 1.1 +/- 0.1 mL)
AID54369Half-maximal inhibition of the COX activity was measured by the direct analysis of the consumed O2 using isolated sheep seminal vesicles; na means Not active2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New indene-derivatives with anti-proliferative properties.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1221972Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID535977Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1077763Prodrug conversion in carrageenan-induced Wistar rat model assessed as sulfide species in serum at 200 mg/kg through gavage administered 1 hr prior to carrageenan-challenge
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1767811Binding affinity to GAL4-DBD-fused PPARgamma ligand binding domain (unknown origin) expressed in HEK293T cells by spectra-fluorophotometry analysis2021European journal of medicinal chemistry, Oct-15, Volume: 222Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1743651Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1136205Analgesic activity in po dosed dog knee joint pain model1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID592742Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1636387Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 6.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID734228Induction of apoptosis in human HCT116 cells assessed as increase in TNFalpha-induced PARP cleavage at 40 uM after 4 hrs by Western blot analysis2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation.
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID364311Activity at PPARgamma in human Caco-2 cells assessed as luciferase activity at 100 uM relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma).
AID161005Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1375692Antiarthritic activity in CFA-induced Sprague-Dawley rat rheumatoid arthritis model assessed as increase in tolerated weight on ipsilateral paw at 6.6 mg/kg, po measured up to 75 mins by paw pressure test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis.
AID1203550Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents after 1 to 4 days by two-electrode voltage clamp assay2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID420790Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced paw edema at 300 umol/kg, po administered 1 hr before carrageenan challenge and measured 3 hrs after carrageenan challenge2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1064291Induction of NO release in glutathione buffer at 400 uM after 1 hr by Griess assay relative to sulindac2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment.
AID1221978Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID420791Gastrointestinal toxicity in Albino mouse assessed ulcer index at 300 mg/kg, po2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.
AID1743652Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1064299Cytotoxicity against human PC3 cells assessed as cell viability at 50 uM after 24 hrs by crystal violet method (Rvb = 99.09 +/- 9.87%)2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment.
AID1203549Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 1 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID681017TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, Sulindac: 1000 uM) in OAT-expressing COS-7 cells1999The Journal of biological chemistry, Jan-15, Volume: 274, Issue:3
Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID104152The compound was evaluated for percent incorporation in DOPC vesicles, when compound to lipid mol ratio is 0.11981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Membrane effects of antiinflammatory agents. 1. Interaction of sulindac and its metabolites with phospholipid membrane, a magnetic resonance study.
AID1136203Analgesic activity in po dosed rat assessed as inhibition of yeast-induced inflammatory pain1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1908942Induction of autophagy in human MIA PaCa-2 cells assessed as accumulation of LC3B marker gene expression at upto 600 uM incubated for 72 hrs by Western blot analysis2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.
AID1221973Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136204Antipyretic activity in po dosed rat1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID1223480Oral clearance in po dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1077803Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay
AID1077806Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay
AID1743646Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID592745Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as reduction of amyloid beta (1 to 42) level at 1 uM after 24 hrs by ELISA relative to control2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1743656Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136209Toxicity in po dosed rat assessed as intestinal perforating ulcer1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID734232Inhibition of RXRalpha in human A549 cells assessed as inhibition of TNFalpha-induced Akt phosphorylation at 30 uM incubated for 1 hr prior to TNFalpha-induction measured after 30 mins by Western blot analysis2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1198257Antiproliferative activity against human U373MG cells assessed reduction in cell number at 1 nM and 10 nM incubated for 1 to 6 days by trypan blue dye exclusion dye based inverted microscopy2015European journal of medicinal chemistry, Mar-26, Volume: 93Effect of new hybrids based on 5,16-pregnadiene scaffold linked to an anti-inflammatory drug on the growth of a human astrocytoma cell line (U373).
AID592844Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as reduction of amyloid beta (1 to 42) level at 10 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID1601156Binding affinity to recombinant human C5a assessed as conformational change =< 1 uM at 4 degC incubated for 1 hr by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1898640Neuroprotective activity against amyloid beta (1 to 42 residues)-induced cell injury in human SH-SY5Y cells assessed as reduction in caspase 3 level2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID568008Inhibition of human recombinant His-tagged glyoxalase 1 expressed in Escherichia coli BL21 (DE3) preincubated for 20 mins by Dixon plot analysis2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
AID1743647Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1636453Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 6.8 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1743645Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1264569Inhibition of recombinant human COX-2 preincubated for 15 mins by fluorescence analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1908811Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.
AID1198256Antiproliferative activity against human U373MG cells assessed as effect on cell number at 1 nM to 10 uM incubated for 1 to 6 days by trypan blue dye exclusion dye based inverted microscopy2015European journal of medicinal chemistry, Mar-26, Volume: 93Effect of new hybrids based on 5,16-pregnadiene scaffold linked to an anti-inflammatory drug on the growth of a human astrocytoma cell line (U373).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1203552Modulation of human alpha7 nAChR expressed in Xenopus laevis oocytes assessed as effect on acetylcholine-induced currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID202033Anti-proliferative activity was evaluated by its ability to inhibit proliferation of SW480 cells2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New indene-derivatives with anti-proliferative properties.
AID1743649Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1801947ALR2 in vitro Inhibition Assay from Article 10.1016/j.bioorg.2016.08.005: \\Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.\\2016Bioorganic chemistry, 10, Volume: 68Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
AID1802103IC50-Activity Assay (AR) from Article 10.1021/acschembio.6b00382: \\IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors\\
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID675701Cytotoxicity against human OVCAR3 cells after 2 days by WST1 assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,392)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990356 (25.57)18.7374
1990's263 (18.89)18.2507
2000's424 (30.46)29.6817
2010's291 (20.91)24.3611
2020's58 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials202 (13.82%)5.53%
Trials0 (0.00%)5.53%
Reviews104 (7.11%)6.00%
Reviews0 (0.00%)6.00%
Case Studies144 (9.85%)4.05%
Case Studies0 (0.00%)4.05%
Observational2 (0.14%)0.25%
Observational0 (0.00%)0.25%
Other1,010 (69.08%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (27)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Phase IIb Trial of Sulindac in Smokers With Bronchial Dysplasia [NCT00368927]Phase 261 participants (Actual)Interventional2006-08-31Completed
Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer [NCT04542135]Phase 2150 participants (Anticipated)Interventional2020-11-20Recruiting
A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy [NCT00068419]Phase 270 participants (Actual)Interventional2004-02-29Completed
Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac [NCT01515137]Phase 147 participants (Actual)Interventional2005-11-30Completed
A Randomized Phase III Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) [NCT01245816]Phase 30 participants (Actual)Interventional2011-03-31Withdrawn
A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS) [NCT04823052]Phase 20 participants (Actual)Interventional2022-05-25Withdrawn(stopped due to Healx has experienced delays to the site activation of the study and this has had an adverse impact on the recruitment timeline which is delaying the progress of other projects in our FXS programme.)
Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck [NCT00392665]Phase 236 participants (Actual)Interventional2006-10-31Terminated(stopped due to slow accrual)
Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma [NCT00755976]Phase 232 participants (Actual)Interventional2007-08-31Completed
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With E [NCT01349881]Phase 3354 participants (Actual)Interventional2013-03-01Active, not recruiting
Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients [NCT01187901]Phase 292 participants (Actual)Interventional2010-04-30Completed
The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon [NCT00176618]60 participants (Anticipated)Interventional2004-04-30Terminated(stopped due to principal Investigator left institution)
A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenocarcinoma Of The Breast [NCT00039520]Phase 210 participants (Actual)Interventional2002-01-31Completed
Phase II Study Of Colorectal ACF Screening, Regression And Prevention In High Risk Participants [NCT00062023]Phase 212 participants (Actual)Interventional2003-06-30Terminated(stopped due to Study closed by the NCI.)
Phase IB Sulindac Study for Women at High Risk for Breast Cancer [NCT00245024]Phase 130 participants (Anticipated)Interventional2005-11-30Completed
Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations [NCT00343629]28 participants (Anticipated)Interventional2006-04-30Completed
Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) [NCT04207944]Phase 2100 participants (Anticipated)Interventional2020-07-10Recruiting
The Effect of Plant Phenolic Compounds on Human Colon Epithelial Cells [NCT00003365]0 participants Interventional1996-08-31Terminated(stopped due to Study completed)
A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO) [NCT01636128]Phase 20 participants (Actual)Interventional2014-03-31Withdrawn(stopped due to Funding and staffing)
A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission [NCT01843179]Phase 20 participants (Actual)Interventional2014-01-31Withdrawn(stopped due to Lack of Funding)
Adenoma-Carcinoma Sequence in the Ileal Pouch Anal Anastomosis in Patients With Familial Adenomatous Polyposis: Studies on Luminal and Mucosal Risk Factors and Chemoprevention [NCT00319007]Phase 230 participants (Anticipated)Interventional2006-04-30Recruiting
A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions [NCT00299195]63 participants (Actual)Interventional2006-02-23Completed
NSAID Effects on Clinical and Imaging Breast Biomarkers [NCT01761877]Phase 2114 participants (Actual)Interventional2012-12-31Completed
Randomized, Phase II Trial of Atorvastatin, RAFTILOSE Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia [NCT00335504]Phase 285 participants (Actual)Interventional2006-03-31Completed
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma [NCT00841204]Phase 250 participants (Actual)Interventional2009-02-28Completed
Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer [NCT01856322]Phase 23 participants (Actual)Interventional2013-04-30Terminated(stopped due to The trial was prematurely closed due to lack of accrual.)
Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis [NCT01483144]Phase 3171 participants (Actual)Interventional2013-10-31Completed
A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon [NCT00118365]Phase 3375 participants (Actual)Interventional1998-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00068419 (3) [back to overview]Percentage of Patients Experiencing a Grade 3 or Higher Adverse Event During Therapy.
NCT00068419 (3) [back to overview]Percentage of Patients Failure Free at 2 Years Following Study Entry
NCT00068419 (3) [back to overview]Percentage of Patients With Tumor Response From Imaging
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Spermidine-to-spermine Ratio Response and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Putrescine Response and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Prostaglandin E2 (PGE2) Response and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Baseline Spermidine-to-spermine Ratio and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Baseline Putrescine and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Baseline Prostaglandin E2 (PGE2) and Treatment
NCT00118365 (21) [back to overview]Biomarker in Adenoma: Sialyl-TN (B72.3)
NCT00118365 (21) [back to overview]Biomarker in Adenoma: CEA
NCT00118365 (21) [back to overview]Biomarker in Adenoma: Bcl-2
NCT00118365 (21) [back to overview]Biomarker in Adenoma: Apoptosis
NCT00118365 (21) [back to overview]At the End of the Study - Spermine Response by ODC Genotype
NCT00118365 (21) [back to overview]At the End of the Study - Spermidine Response by ODC Genotype
NCT00118365 (21) [back to overview]At the End of the Study - Putrescine Response by ODC Genotype
NCT00118365 (21) [back to overview]Number of Participants Have Adenoma Recurrence in Each ODC1 Genotytpe by Treatment Group
NCT00118365 (21) [back to overview]Baseline Spermine by ODC Genotype
NCT00118365 (21) [back to overview]Baseline Spermidine by ODC Genotype
NCT00118365 (21) [back to overview]Baseline Putrescine by ODC Genotype
NCT00118365 (21) [back to overview]Adverse Events With a Grade of 3 and Above
NCT00118365 (21) [back to overview]Biomarker in Adenoma - p53
NCT00118365 (21) [back to overview]Biomarker in Adenoma - Ki-67
NCT00335504 (4) [back to overview]Effects on Apoptosis (Caspase-3 Expression).
NCT00335504 (4) [back to overview]Effects on Proliferation (Ki67 Expression).
NCT00335504 (4) [back to overview]Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF) as Measured by Magnification Chromoendoscopy
NCT00335504 (4) [back to overview]Adverse Events.
NCT00368927 (2) [back to overview]Percentage of Participants With Response Determined by Change in Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples Before and After Treatment
NCT00368927 (2) [back to overview]Percent Change in Number of Dysplastic Lesions (DL) as Measured by Mucosal Biopsy Samples Before and After the Intervention
NCT00392665 (4) [back to overview]Efficacy of Erlotinib Plus Bevacizumab (Arm A) or Erlotinib Plus Sulindac (Arm B) as Measured by Progression-free Survival.
NCT00392665 (4) [back to overview]Number of Participants With Toxicities According to Severity
NCT00392665 (4) [back to overview]Overall Response Rate (ORR)
NCT00392665 (4) [back to overview]Duration of Overall Survival
NCT00841204 (8) [back to overview]Sulindac Sulfide, an Active Metabolite of Sulindac, Concentration in the Nevi
NCT00841204 (8) [back to overview]Sulindac Sulfone, an Active Metabolite of Sulindac, Concentration in the Nevi
NCT00841204 (8) [back to overview]Sulindac Effects on Vascular Endothelial Growth Factor (VEGF) Expression in Atypical Nevi
NCT00841204 (8) [back to overview]Sulindac Effects on Apoptosis in Atypical Nevi
NCT00841204 (8) [back to overview]Sulindac Concentration in the Nevi (Moles)
NCT00841204 (8) [back to overview]Association Between Plasma and Target Tissue Sulindac Sulfone Levels
NCT00841204 (8) [back to overview]Association Between Plasma and Target Tissue Sulindac Sulfide Levels
NCT00841204 (8) [back to overview]Association Between Plasma and Target Tissue Sulindac Levels
NCT01187901 (6) [back to overview]Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants
NCT01187901 (6) [back to overview]Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants
NCT01187901 (6) [back to overview]Change in Number of Duodenal Polyps From Baseline to 6 Months
NCT01187901 (6) [back to overview]Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants
NCT01187901 (6) [back to overview]Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants
NCT01187901 (6) [back to overview]Change in Duodenal Polyp Burden From Baseline to 6 Months
NCT01483144 (3) [back to overview]Improvement in Investigator Lower GI Assessment
NCT01483144 (3) [back to overview]Improvement in Investigator Upper GI Assessment
NCT01483144 (3) [back to overview]Number of Subjects With Any FAP-related Event.
NCT01761877 (3) [back to overview]Muscle and Joint Pain and Stiffness
NCT01761877 (3) [back to overview]Change in Mean Arterial Blood Pressure at 12 Months
NCT01761877 (3) [back to overview]Change in Breast Density Measured as Fat to Water Ratio by Magnetic Resonance Imaging

Percentage of Patients Experiencing a Grade 3 or Higher Adverse Event During Therapy.

The percentage of patients experiencing a grade 3 or higher adverse event as assessed by the National Cancer Institute Common Toxicity Terminology for Adverse Events v3.0 (NCT00068419)
Timeframe: Up to 12 months

InterventionPercentage of participants (Number)
Treatment (Enzyme Inhibitor Therapy, Anti-estrogen Therapy)3.4

[back to top]

Percentage of Patients Failure Free at 2 Years Following Study Entry

Kaplan Meier estimate of failure free survival at 2 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00068419)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Treatment (Enzyme Inhibitor Therapy, Anti-estrogen Therapy)36

[back to top]

Percentage of Patients With Tumor Response From Imaging

Percentage of patients with a tumor response where tumor response is assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) (NCT00068419)
Timeframe: Baseline up to 5 years

InterventionPercentage of participants (Number)
Treatment (Enzyme Inhibitor Therapy, Anti-estrogen Therapy)8.0

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Spermidine-to-spermine Ratio Response and Treatment

Spermidine-to-spermine ratio responder = ratios at 36-month are decreased by >=30% from baseline Spermidine-to-spermine ratio nonresponder = ratios at 36-month are increased, or decreased by < 30% from baseline The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + Spd:Spm Nonresponders830
Eflornithine and Sulindac + Spd:Spm Responders875
Placebo + Spd:Spm Nonresponders3344
Placebo + Spd:Spm Responders1724

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Putrescine Response and Treatment

Putrescine responder = Putrescine values at 36-month are decreased by >=30% from baseline Putrescine nonresponder = Putrescine values at 36-month are increased, or decreased by < 30% from baseline The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + Putrescine Nonresponders753
Eflornithine and Sulindac + Putrescine Responders952
Placebo + Putrescine Nonresponders2844
Placebo + Putrescine Responders2224

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Prostaglandin E2 (PGE2) Response and Treatment

PGE2 Responder = PGE2 values at 36-month are decreased by >=30% in PGE2 values from baseline PGE2 nonresponder = PGE2 values at 36-month are increased, or decreased by < 30% from baseline The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + PGE2 Nonresponders827
Eflornithine and Sulindac + PGE2 Responders110
Placebo + PGE2 Nonresponders1517
Placebo + PGE2 Responders413

[back to top]

Detection of Any Adenoma at the End of the Study

Detection of any adenoma at the end of the study. This analysis is based on the participants who had the end-of-study colonscopy procedure done. (NCT00118365)
Timeframe: Up to 36 months

,
Interventionparticipants (Number)
YesNo
Arm I (Eflornithine and Sulindac)17121
Arm II (Placebo)5376

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Baseline Spermidine-to-spermine Ratio and Treatment

"The low is defined as the ratios that are below the median spermidine-to-spermine ratio in the analysis cohort. The high is defined as the ratios that are above the median spermidine-to-spermine ratio in the analysis cohort.~In the finalized datasaet, the total number of adnoma detected in the placebo group is 55. The descrepancy in the total number of adnoma detected in placebo group between Outcome Measure 1 and this oucome is due to the revolution of the datatset.~The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: Up 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + High Spd:Spm at Baseline1260
Eflornithine and Sulindac + Low Spd:Spm at Baseline559
Placebo + High Spd:Spm at Baseline2437
Placebo + Low Spd:Spm at Baseline3137

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Baseline Putrescine and Treatment

The low is defined as the values that are below the median putrescine level in the analysis cohort. The high is defined as the values that are above the median putrescine level in the analysis cohort. (NCT00118365)
Timeframe: Up 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + High Putrescine at Baseline1056
Eflornithine and Sulindac + Low Putrescine at Baseline763
Placebo + High Putrescine at Baseline3136
Placebo + Low Putrescine at Baseline2438

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Baseline Prostaglandin E2 (PGE2) and Treatment

This analysis is based on the participants who had the end-of-study colonscopy procedure done and their baseline PGE2 values are available. The low PGE2 is defined as the values that are below the median PGE2 value in the analysis cohort. The high PGE2 is defined as the values that are above the median PGE2 value in the analysis cohort. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + High PGE2 at Baseline341
Eflornithine and Sulindac + Low PGE2 at Baseline1241
Placebo + High PGE2 at Baseline2132
Placebo + Low PGE2 at Baseline1923

[back to top]

Biomarker in Adenoma: Sialyl-TN (B72.3)

sialyl-Tn (B72.3) is adenocarcinoma tissue marker that is expressed during adenoma formation. (NCT00118365)
Timeframe: At the end of the study

,
InterventionAdenoma (Number)
a pattern equal to normal mucosa1.<10% of the cells in the adenoma showed staining2.10-50% cells showed staining3.>50% cells showed stainingInsufficient tissue
Arm I (Eflornithine and Sulindac)37200
Arm II (Placebo)11321751

[back to top]

Biomarker in Adenoma: CEA

carcino-embryonic antigen (CEA) is adenocarcinoma tissue marker that is expressed during adenoma formation. (NCT00118365)
Timeframe: At the end of the study

,
InterventionAdenoma (Number)
A pattern equal to normal mucosa1.<50% of cells showed staining2.50-90% of cells showed staining3.>90% of cells showed stainingInsufficient tissue
Arm I (Eflornithine and Sulindac)15600
Arm II (Placebo)5153592

[back to top]

Biomarker in Adenoma: Bcl-2

bcl-2 is the anti-apoptotic protein BCL2 (NCT00118365)
Timeframe: At the end of the study, up to 3 years

,
InterventionAdenoma (Number)
A pattern equal to normal mucosa1.<10% of the cells in the adenoma showed staining2.10-50% cells showed staining3.>50% cells showed stainingInsufficient tissue
Arm I (Eflornithine and Sulindac)44310
Arm II (Placebo)17251482

[back to top]

Biomarker in Adenoma: Apoptosis

Apoptosis expression was assessed using cytoplasmic staining. The definitions for the category level for the Apoptosis are: 1. focal (less than 10% cells that are positively stained); 2. less than 50% cells are positively stained; 3. more than 50% cells are positively stained. (NCT00118365)
Timeframe: At the end of the study

,
Interventionadenoma (Number)
A pattern equal to normal mucosa1.focal (<10%)2.cyto less than 50%3.cyto more than 50%
Arm I (Eflornithine and Sulindac)2712
Arm II (Placebo)4202313

[back to top]

At the End of the Study - Spermine Response by ODC Genotype

"Spermine responder was defined as (tissue spermine value at baseline - tissue spermine value at the end of the study)/(tissue spermine value at baseline) ≥ the threshold. Spermine non-responder was defined as (tissue spermine value at baseline - tissue spermine value at the end of the study)/(tissue spermine value at baseline) < the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.~ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: At the end of the study

,,,
Interventionparticipants (Number)
ResponderNon-Responder
DFMO + Sulindac - AA/GA733
DFMO + Sulindac - GG751
Placebo - AA/GA1039
Placebo - GG1825

[back to top]

At the End of the Study - Spermidine Response by ODC Genotype

"Spermidine responder was defined as (tissue spermidine value at baseline - tissue spermidine value at the end of the study)/(tissue spermidine value at baseline) ≥ the threshold. Spermidine non-responder was defined as (tissue spermidine value at baseline - tissue spermidine value at the end of the study)/(tissue spermidine value at baseline) < the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.~ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: At the end of the study

,,,
Interventionparticipants (Number)
ResponderNon-Responder
DFMO + Sulindac - AA/GA1228
DFMO + Sulindac - GG2532
Placebo - AA/GA1138
Placebo - GG1528

[back to top]

At the End of the Study - Putrescine Response by ODC Genotype

"Putrescine responder was defined as (tissue putrescine value at baseline - tissue putrescine value at the end of the study)/(tissue putrescine value at baseline) ≥ the threshold. Putrescine non-responder was defined as (tissue putrescine value at baseline - tissue putrescine value at the end of the study)/(tissue putrescine value at baseline) < the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.~ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: At the end of the study

,,,
Interventionparticipants (Number)
ResponderNon-Responder
DFMO + Sulindac - AA/GA2119
DFMO + Sulindac - GG2632
Placebo - AA/GA1237
Placebo - GG1231

[back to top]

Number of Participants Have Adenoma Recurrence in Each ODC1 Genotytpe by Treatment Group

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

Interventionparticipants (Number)
DFMO + Sulindac - GG7
DFMO + Sulindac - AA/GA9
Placebo - GG22
Placebo - AA/GA18

[back to top]

Baseline Spermine by ODC Genotype

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Baseline

Interventionnmol/mg protein (Median)
ODC1 AA/GA6.82
ODC1 GG7.29

[back to top]

Baseline Spermidine by ODC Genotype

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Baseline

Interventionnmol/mg protein (Median)
ODC1 AA/GA1.99
ODC1 GG2.17

[back to top]

Baseline Putrescine by ODC Genotype

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Baseline

Interventionnmol/mg protein (Median)
ODC1 AA/GA0.47
ODC1 GG0.56

[back to top]

Adverse Events With a Grade of 3 and Above

"Participants reported at least 1 adverse event with a grade of 3 and above, regardless if the event is defined as serious per protocol or other.~Per protocol, not all grade 3 events are considered as serious events." (NCT00118365)
Timeframe: Up to 36 months

Interventionparticipants (Number)
Arm I (Eflornithine and Sulindac)46
Arm II (Placebo)37

[back to top]

Biomarker in Adenoma - p53

"Estimated mean percent of cells staining postivie for p53 based on GEE approach with adjument for covariates.~Tumor protein p53, also known as p53, cellular tumor antigen p53, phosphoprotein p53, or tumor suppressor p53, is a protein that in humans is encoded by the TP53 gene." (NCT00118365)
Timeframe: At the end of the study

Interventionpercentage of cells that are positive (Mean)
Arm I (Eflornithine and Sulindac)75.6
Arm II (Placebo)70.3

[back to top]

Biomarker in Adenoma - Ki-67

Estimated mean percent of cells staining postivie for the Ki-67 based on the GEE approach with adjustment for covariates (NCT00118365)
Timeframe: At the end of the study

Interventionpercentage of cells that are positive (Mean)
Arm I (Eflornithine and Sulindac)59.5
Arm II (Placebo)63.9

[back to top]

Effects on Apoptosis (Caspase-3 Expression).

Tissue is examined by immunohistochemistry for cleaved caspase-3. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms. (NCT00335504)
Timeframe: Up to 6 months

InterventionPercent change of caspase-3 (Mean)
Arm I (Atorvastatin Calcium)106.0
Arm II (Sulindac)131.9
Arm III (Oligofructose-enriched Inulin)120.5
Arm IV (Placebo)130.6

[back to top]

Effects on Proliferation (Ki67 Expression).

Tissue is examined by immunohistochemistry for Ki67. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms. (NCT00335504)
Timeframe: Up to 6 months

InterventionPercent change (Mean)
Arm I (Atorvastatin Calcium)6.5
Arm II (Sulindac)12.2
Arm III (Oligofructose-enriched Inulin)34.7
Arm IV (Placebo)13.6

[back to top]

Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF) as Measured by Magnification Chromoendoscopy

At the Pre-Intervention Evaluation, rectal ACF will be classified with respect to ACF number, crypt number, crypt size, tissue plane, staining intensity, and (optional) lumen shape for each subject. At the Post- Intervention Evaluation, these same parameters will be recorded and incident vs prevalent rectal ACF status will also be recorded. Compare each non-placebo arms versus the placebo arm to screen the three active study agents for possible phase III testing. (NCT00335504)
Timeframe: 6 months

Interventionpercent change in number of ACF (Mean)
Arm I (Atorvastatin Calcium)8.4
Arm II (Sulindac)-13.3
Arm III (Oligofructose-enriched Inulin)-8.8
Arm IV (Placebo)-8.6

[back to top]

Adverse Events.

Defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with participation in a study, whether or not related to that participation. Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 3.0. Number of adverse events per grade level. (NCT00335504)
Timeframe: Up to 30 days after completion of study treatment

,,,
Interventionadverse events (Number)
Grade 1Grade 2Grade 3
Arm I (Atorvastatin Calcium)1152
Arm II (Sulindac)1242
Arm III (Oligofructose-enriched Inulin)1040
Arm IV (Placebo)15131

[back to top]

Percentage of Participants With Response Determined by Change in Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples Before and After Treatment

Definition of response: complete response = regression of all dysplastic lesions (DL) to normal, hyperplasia or metaplasia with no new DL identified; partial response = regression of one or more, but not all of the DL with no new DL identified and no lesions worsening; progression = worsening at one or more sites by at least 2 histologic grades or appearance of any new DL that were not previously biopsied; stable disease = participants not classified as having a complete response, partial response, or progressive disease (NCT00368927)
Timeframe: Baseline and 6 months

,
Interventionpercentage of participants (Number)
Complete responsePartial responseStableProgression
Arm A (Sulindac)38.519.211.530.8
Arm B (Placebo)48.27.47.437.0

[back to top]

Percent Change in Number of Dysplastic Lesions (DL) as Measured by Mucosal Biopsy Samples Before and After the Intervention

The number of dysplastic lesions was recorded pre-intervention and post-intervention for each participant in each group. Change in the number of lesions was compared between the two intervention groups. (NCT00368927)
Timeframe: Baseline and 6 months

InterventionPercent change in number of DL (Median)
Arm A (Sulindac)-55
Arm B (Placebo)-100

[back to top]

Efficacy of Erlotinib Plus Bevacizumab (Arm A) or Erlotinib Plus Sulindac (Arm B) as Measured by Progression-free Survival.

The primary outcome will be measured by median progression-free survival (PFS), determined by the Kaplan-Meier method for both Arm A and Arm B. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00392665)
Timeframe: 1 year

Interventionmonths (Median)
Erlotinib + Bevacizumab9.38
Erlotinib + Sulindac7.01

[back to top]

Number of Participants With Toxicities According to Severity

Toxicities by Grades 1 or 2 and Grades 3 or 4 in each arm. Grade 4 = life-threatening, Grade 3 = serious, Grade 2 = moderate, Grade 1 = Mild (NCT00392665)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Fatigue72408051Fatigue72408052Rash72408051Rash72408052Diarrhea72408051Diarrhea72408052Hypertension72408051Hypertension72408052Oral cavity pain72408051Oral cavity pain72408052Dry skin72408051Dry skin72408052Hearing problems72408051Hearing problems72408052Dyspepsia72408052Dyspepsia72408051Dry mouth72408051Dry mouth72408052Constipation72408051Constipation72408052Anorexia72408051Anorexia72408052Dehydration72408051Dehydration72408052Dyspnea72408051Dyspnea72408052Mucositis72408051Mucositis72408052Neuropathy-sensory72408052Neuropathy-sensory72408051Hemmorrhage72408051Hemmorrhage72408052Nausea72408051Nausea72408052Vomiting72408051Vomiting72408052Insomnia72408051Insomnia72408052Pruritus72408051Pruritus72408052Hypomagnesemia72408051Hypomagnesemia72408052
Did not haveGrades 1 or 2Grades 3 or 4
Erlotinib + Bevacizumab10
Erlotinib + Sulindac8
Erlotinib + Bevacizumab14
Erlotinib + Sulindac15
Erlotinib + Bevacizumab4
Erlotinib + Sulindac1
Erlotinib + Sulindac2
Erlotinib + Sulindac0
Erlotinib + Sulindac9
Erlotinib + Bevacizumab18
Erlotinib + Sulindac3
Erlotinib + Bevacizumab6
Erlotinib + Bevacizumab12
Erlotinib + Sulindac18
Erlotinib + Bevacizumab2
Erlotinib + Bevacizumab16
Erlotinib + Bevacizumab8
Erlotinib + Bevacizumab0
Erlotinib + Sulindac16

[back to top]

Overall Response Rate (ORR)

"Overall response rate (complete plus partial response=ORR), as determined by RECIST.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00392665)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Erlotinib + Bevacizumab11.1
Erlotinib + Sulindac11.1

[back to top]

Duration of Overall Survival

Median overall survival (OS), determined by the Kaplan-Meier method. (NCT00392665)
Timeframe: 2 years

Interventionmonths (Median)
Erlotinib + Bevacizumab9.38
Erlotinib + Sulindac8.82

[back to top]

Sulindac Sulfide, an Active Metabolite of Sulindac, Concentration in the Nevi

(NCT00841204)
Timeframe: 8 weeks

Interventionµg/g tissue (Mean)
Sulindac0.12
Placebo0

[back to top]

Sulindac Sulfone, an Active Metabolite of Sulindac, Concentration in the Nevi

(NCT00841204)
Timeframe: 8 weeks

Interventionµg/g tissue (Mean)
Sulindac1.38
Placebo0

[back to top]

Sulindac Effects on Vascular Endothelial Growth Factor (VEGF) Expression in Atypical Nevi

Change in VEGF expression in melanocytic junctional component (NCT00841204)
Timeframe: Baseline and 8 weeks

Intervention% of stained cells * intensity score (Median)
Sulindac23
Placebo0

[back to top]

Sulindac Effects on Apoptosis in Atypical Nevi

Change in the expression of a marker of apoptosis, cleaved caspase 3, in melanocytic junctional component (NCT00841204)
Timeframe: Baseline and 8 weeks

Intervention% of stained cells * intensity score (Median)
Sulindac3
Placebo-25

[back to top]

Sulindac Concentration in the Nevi (Moles)

(NCT00841204)
Timeframe: 8 weeks

Interventionµg/g tissue (Mean)
Sulindac0.51
Placebo0

[back to top]

Association Between Plasma and Target Tissue Sulindac Sulfone Levels

(NCT00841204)
Timeframe: 8 weeks

Interventioncorrelation coefficient (Number)
Arm I0.13

[back to top]

Association Between Plasma and Target Tissue Sulindac Sulfide Levels

(NCT00841204)
Timeframe: 8 weeks

Interventioncorrelation coefficient (Number)
Arm I0.33

[back to top]

Association Between Plasma and Target Tissue Sulindac Levels

(NCT00841204)
Timeframe: 8 weeks

Interventioncorrelation coefficient (Number)
Arm I0.41

[back to top]

Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants

A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count) (NCT01187901)
Timeframe: Baseline and 6 months

Interventionpolyps (Median)
Sulindac-erlotinib-2.1
Placebo4.0

[back to top]

Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants

A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count) (NCT01187901)
Timeframe: Baseline and 6 months

Interventionpolyps (Median)
Sulindac-erlotinib-4.3
Placebo4.9

[back to top]

Change in Number of Duodenal Polyps From Baseline to 6 Months

A comparison between the Sulindac-erlotinib and Placebo arms of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count). (NCT01187901)
Timeframe: Baseline and 6 months

Interventionpolyps (Median)
Sulindac-erlotinib-2.8
Placebo4.3

[back to top]

Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants

A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden). (NCT01187901)
Timeframe: Baseline and 6 months

Interventionmm (Median)
Sulindac-erlotinib-8.5
Placebo8.5

[back to top]

Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants

A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden). (NCT01187901)
Timeframe: Baseline and 6 months

Interventionmm (Median)
Sulindac-erlotinib-8.0
Placebo7.0

[back to top]

Change in Duodenal Polyp Burden From Baseline to 6 Months

A comparison between the Sulindac-erlotinib and Placebo arms of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden). (NCT01187901)
Timeframe: Baseline and 6 months

Interventionmm (Median)
Sulindac-erlotinib-8.5
Placebo8.0

[back to top]

Improvement in Investigator Lower GI Assessment

Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment

,,
InterventionParticipants (Count of Participants)
ImprovedNot Improved
Eflornithine Plus Sulindac2234
Eflornithine Plus Sulindac Placebo1641
Sulindac Plus Eflornithine Placebo2236

[back to top]

Improvement in Investigator Upper GI Assessment

Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment

,,
InterventionParticipants (Count of Participants)
ImprovedNot Improved
Eflornithine Plus Sulindac1145
Eflornithine Plus Sulindac Placebo1047
Sulindac Plus Eflornithine Placebo1048

[back to top] [back to top]

Muscle and Joint Pain and Stiffness

The endpoint for arthralgia is change from baseline in Total Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index scores on a scale at 12 months. The Western Ontario and McMaster Universities Index is a self-administered questionnaire consisting of 24 items divided in 3 subscales: Pain, Stiffness, and Physical Function. Scores on the scale range from 0 to 96 for total WOMAC where 0 represents the best health status and 96 the worst possible status. (NCT01761877)
Timeframe: Baseline and 12 months

Interventionscore on a scale (Mean)
Sulindac (Clinoril)-5.85
Observational-0.25

[back to top]

Change in Mean Arterial Blood Pressure at 12 Months

Adjusted estimate of change in mean arterial blood pressure in each study arm at 12 months in each study arm. (NCT01761877)
Timeframe: Change in blood pressure between Baseline and 12 months

Interventionmm Hg (Mean)
Sulindac0.77
Observational1.52

[back to top]

Change in Breast Density Measured as Fat to Water Ratio by Magnetic Resonance Imaging

Adjusted estimates of relative change in percent breast density by magnetic resonance imaging (NCT01761877)
Timeframe: Baseline and 12 months

Interventionpercent change in breast density (Mean)
Sulindac (Clinoril)-9.8
Observational-3.6

[back to top]